Clinical trialObsUnknown
Quebec Pancreas Cancer Study
- Outcome
- Outcome unknown
- Phase
- Obs
- Status
- Unknown
- Study type
- Observational
- Start
- 12 March 2012
- Expected end
- January 2025
- Enrollment
- 2,000 participants
- Sites
- 1
- Primary outcomes
- Knowledge and Tissue Bank
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 April 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.
Detailed description public domain (ClinicalTrials.gov)
The objectives of the QPCS are as follows: 1. To study the epidemiology of pancreas cancer, related cancers and related pre-cancerous conditions, including the risk factors and patient outcomes. 2. To characterize the contribution of known hereditary cancer syndromes to pancreas cancer, related cancers, and related pre-cancerous conditions. 3. To identify new genetic and epigenetic changes associated with hereditary pancreas cancer, related cancers, and related pre-cancerous conditions. DNA contains the instructions used in the development and functioning of living organisms, including humans. Epigenetic changes are changes other than changes in the underlying DNA sequence. 4. To study the tumour biology of pancreas cancer and related pre-cancerous conditions. This may include studying the tumour and the environment surrounding the tumour, as well as blood and/or saliva samples. The studies may include characterization of genetic, genomic, transcriptomic, epigenetic, proteomic, and metabolomic changes. 5. To identify and characterize biomarkers associated with pancreas cancer, related cancers and related pre-cancerous conditions. 6. To determine if there are any epidemiological, clinical and outcome (for example, overall survival) associations with the genetic, genomic, epigenetic, transcriptomic, proteomic, metabolomic or other biologic changes that occur in pancreas cancer, related cancers and related pre-cancerous conditions.
Papers 5
- BackgroundReflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinic… DOI 10.1200/po.17.00098↗
- BackgroundReg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ducta… DOI 10.18632/oncotarget.12834↗
- BackgroundCandidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. DOI 10.1016/j.canlet.2015.10.030↗
- BackgroundIncreased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2… DOI 10.1016/j.canlet.2015.04.003↗
- BackgroundEstablishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. DOI 10.3747/co.22.2300↗